Sareum Holdings Plc · LSE:SAR
Sareum — H1 2022 Earnings Presentation
13 slides from Sareum's earnings presentation, Feb 28, 2022
Slide 1: Half-Year Results 28 February 2022
Specialists in Small Molecule Drug Development Half-Year Results 28 February 2022 Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO and Co-Founder www.sareum.co.uk
Slide 2: Disclaimer
Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have profession
Slide 3: Advancing our Pipeline
Advancing our Pipeline • 100% focused on development of our proprietary TYK2/JAK1 inhibitors Lead Candidate Clinical Clinical Target Preclinical Potential indications optimisation selection Phase I Phase II Autoimmune Psoriasis, RA, lupus, IBD, MS diseases Severe SDC-1801 Proprietary TYK2/JAK1 Respi
Slide 4: Recent Highlights
Recent Highlights • SDC-1801 – Autoimmune diseases and acute respiratory symptoms of Covid-19 • Progress made towards clinical development – successfully completed final toxicology/safety studies in Q4 2021 • Preliminary data analysis fully supports filing of CTA for first-in-human clinical studies,
Slide 5: TYK/JAK Inhibitors are Emerging Targets of Increasing Industry Interest
TYK/JAK Inhibitors are Emerging Targets of Increasing Industry Interest • The TYK/JAK cell signalling family (TYK2, JAK1, JAK2, JAK3) is important for maintaining a healthy immune system • Strong clinical validation (BMS, Pfizer) for TYK2 and TYK2/JAK1 in psoriasis and psoriatic arthritis • Mid-stag
Slide 6: JAK Inhibition on Signalling of Key Immunoregulatory Cytokines
JAK Inhibition on Signalling of Key Immunoregulatory Cytokines RA, Psoriasis, IBD, Lupus, Therapeutic Resistance to I/O, Resistance to I/O, Psoriasis, IBD, RA, Lupus RA, respiratory failure opportunities Viral/bacterial Viral/bacterial from viral infections pneumonia pneumonia JAK2 and JAK3 inhibiti
Slide 7: We are Focused on Selective, Potent TYK2/JAK1 Inhibitors
We are Focused on Selective, Potent TYK2/JAK1 Inhibitors Significant clear opportunities available to Sareum • No marketed products with selectivity for TYK2 – important for differentiation • No selective TYK2 inhibitors in clinical trials for cancer – first-in-class opportunity SDC-1801 and SDC-180
Slide 8: SDC-1801 – Autoimmune Diseases
SDC-1801 – Autoimmune Diseases Timeline and Development Strategy • Internal focus on progressing SDC-1801 into first-in-human (Phase 1a) clinical trial • Consultants appointed to assist in developing plan and selecting initial indication for clinical studies • Seek development partners for commercia
Slide 9: SDC-1802: Targeting Multiple Cancers
SDC-1802: Targeting Multiple Cancers • Good efficacy in immunotherapy disease models vs many cancers • Anti-tumour effects seen in models of kidney, colorectal & skin cancers and B-cell lymphoma • Evidence that SDC-1802 induces anti-cancer activity through a novel immunotherapeutic mechanism • Posit
Slide 10: SRA737: Current Development Status
SRA737: Current Development Status Sierra Oncology Corporate Presentation – posted on website 11/01/22 • $550,000 milestone payment to Sareum upon achievement of the next milestone event (first patient in next clinical trial) • Eligible for up to $79.75M in total milestone payments, plus royalties •
Slide 11: Income Statement
Income Statement Unaudited Unaudited Audited Six months Six months Year ended ended ended 31 Dec 21 31 Dec 20 30 June 21 £’000 £’000 £’000 Revenue - - -) Other operating income - - 171) Operating expenses (1,017) (594) (1,875) Share of loss of associates - (16) (14) Operating loss (1,718) Finance in
Slide 12: Balance Sheet
Balance Sheet Unaudited Unaudited Audited As at As at As at 31 Dec 21 31 Dec 21 30 June 21 £’000 £’000 £’000 Non-current assets Computers and equipment 3) 2) 2) Investments in associates 25) 23) 26) 28) 25) 27) Current assets Debtors 236) 283) 366) Cash and cash equivalents 5,613) 1,580) 2,686) 3,05
Slide 13: Potential Milestones & Value Drivers 2022
Potential Milestones & Value Drivers 2022 TYK2/JAK1 • • SDC-1801 CTA submission (mid-2022) • Phase 1a clinical trial start for SDC-1801 (H2 2022)* • Selection of initial indication for Phase 1b trial Proprietary pipeline • Updates on SDC-1802 preclinical progress Chk1 • (SRA737) • Potential advancem